Table 2.
Comparison of demographic features, clinical characteristics and treatment between SLE patients with graft failure and functioning graft.
| Graft failure (n = 15) | Functioning graft (n = 35) | P | |
|---|---|---|---|
| Gender female (%) | 14 (93%) | 27 (77%) | 0.169 |
| Age at diagnosis SLE (years) | 22.4 ± 10 | 22.8 ± 11 | 0.758 |
| Age at renal Tx (years) | 41.3 ± 10.2 | 38.7 ± 12.0 | 0.280 |
| Time SLE-nephritis (months) | 17 ± 42.6 | 34.9 ± 75 | 0.412 |
| Time nephritis dialysis (months) | 39 ± 45.5 | 88.7 ± 80.6 | 0.038 |
| Time on dialysis (months) | 73.9 ± 60.6 | 35.7 ± 35.4 | 0.011 |
| Time nephritis-Tx (months) | 114.6 ± 64.2 | 120 ± 73.3 | 0.880 |
| Dialysis before renal Tx (%): | |||
| HD | 14 (93.3%) | 19 (76.0%) | 0.168 |
| CAPD | 2 (13.3%) | 7 (28.0%) | 0.251 |
| HD and CAPD | 1 (6.7%) |
3 (12.0%) | 0.516 |
| Tx date (years) | 1998 ± 7 | 2004 ± 6 | 0.036 |
| Donor source (%): | |||
| Cadaveric | 13 (86.7%) | 16 (45.7%) | 0.007 |
| Living donor | 2 (13.3%) | 19 (54.3%) | — |
| Immunosuppressive regimen at Tx (grafts) (%): | |||
| Cyclosporine A | 10 (66.6%) | 9 (25.7%) | 0.006 |
| Mycophenolic acid | 8 (53%) | 31 (88.6%) | 0.003 |
| Tacrolimus | 4 (27%) | 23 (66%) | 0.012 |
| Positive anti-HCV antibodies (patients) (%) | 12 (80%) | 10 (28.6%) | 0.001 |
| Positive aPL antibodies (%) | 1 (6.7%) | 11 (31.4%) | 0.058 |
Quantitative variables are presented as mean ± standard deviation and qualitative variables as number (percentage).
SLE: systemic lupus erythematosus; Tx: transplantation; HD: hemodialysis; CAPD: continuous ambulatory peritoneal dialysis; HCV: hepatitis C virus; aPL: anti-phospholipid antibodies.